Zai picks up GSK inflammation candidates

12:39 EDT 18 Oct 2016 | BioCentury

Zai Lab Ltd. (Shanghai, China) said it gained exclusive, worldwide rights to two undisclosed candidates from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Both have applications in multiple anti-inflammatory indications, Zai said.

Financial terms and the candidates' targets were undisclosed. Zai COO Marietta Wu told BioCentury the company plans to begin a Phase II trial of one of the products this year, and that the second is in preclinical testing.

Original Article: Zai picks up GSK inflammation candidates


More From BioPortfolio on "Zai picks up GSK inflammation candidates"

Quick Search

Relevant Topics

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...